Intraviteal Bevacizumab (Avastin(R)) Injection for the Treatment of Early-Stage Neovascular Glaucoma

ABSTRACT

PURPOSE: This case is conducted to assess the short term safety and efficacy of intravitreal bevacizumab injection in patient with early stage of the neovascular glaucoma (NVG) without peripheral anterior synechiae. CASE SUMMARY: A 66 year old patient with a history of proliferative diabetic retinopathy presented with neovascularization of the iris and the angle and high intraocular pressure of 30 mmHg. The patient received a single injection of bevacizumab (1.25 mg /0.05 mg) intravitreally. The visual acuity (VA), intraocular pressure (IOP), regression of the iris and the angle neovascularization were measured up to the twenty ninth week after injection. Regression of the iris and angle neovascularization were confirmed from the second week after injection. The visual acuity had continued stable and the IOP had been controlled from 30 mmHg to 20 mmHg from fifth week without the need for topical antiglaucoma medications until the twenty ninth week. CONCLUSIONS: Bevacizumab may be an effective medication for the treatment of neovascular glaucoma. Bevacizumab seems to be a useful adjunct or an advantageous treatment option to panretinal photocoagulation in the treatment of neovascular glaucoma.